Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer

Bookmark and Share
Published: 25 Oct 2018
Views: 2474
Rating:
Save
Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy

Dr Pietrantonio speaks to ecancer at the ESMO 2018 congress in Munich about the TRIBE-2 study for patients with metastatic colorectal cancer.

Dr Pietrantonio believes the TRIBE-2 trial is very important as it is setting a new standard in first and second line treatment of metastatic colorectal cancer patients independently on molecular selection.

He also spoke with ecancer about the VALENTINO study, here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

 

I wanted to cite briefly the results of the TRIBE-2 study. This was an Italian phase III study that was led by the GONO group. We all participated in this very large trial. This trial is an honour for all Italy and will be presented tomorrow by Dr Chiara Cremolini, who is a friend of mine actually. This trial is very important because it’s setting a new standard for first and second line treatment of metastatic colorectal cancer patients independently of molecular selection.

So the study results are impressive since the primary study endpoint that was actually PFS2, meaning the time elapsed from randomisation to progressive disease on second line treatment, so this was a strategy trial, the primary endpoint was met. So I really think the option of FOLFOXIRI plus bevacizumab in the up-front setting is again confirmed, also, when considering post-progression treatment that may be given to our patients.